Contribute Try STAT+ Today

In a setback to AbbVie (ABBV), a U.S. federal court judge dismissed a lawsuit in which the drug maker claimed a would-be rival hired one of its employees, who then allegedly transferred a boatload of confidential information about its best-selling Humira treatment.

AbbVie had contended that Alvotech recruited Rongzan Ho in its quest to jumpstart its entry into the market for biosimilar versions of Humira. The biologic treatment is widely prescribed to combat rheumatoid arthritis, among other ailments, and racked up $19.8 billion in worldwide sales last year, including $16.1 billion in the U.S. The medicine accounted for 43% of its revenue.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment